Top Pharmaceutical Stocks for 2013 Crown Marketing Inc., Pfizer Inc., Merck & Co. Inc., and Eli Lilly and Company

Crown Marketing Inc. has recently patented a controlled drug delivery technology that aims not only to improve the safety and pharmacokinetics of controlled-release medication, but also to streamline the manufacturing process for existing facilities without significantly increasing costs. Crown Marketing is seeking to change the time-release process entirely, providing a true 24-hour sustained-release delivery system.

Crown Marketing has also announced that the smart drug delivery revolution has officially arrived.

Read the entire press release issued by Crown Marketing Inc. here: http://finance.yahoo.com/news/crown-marketing-announces-smart-drug-175924186.html

Pfizer Inc. has been the buzz of Wall Street with rumors circulating that the company will split its drug division in two. President Geno Germano said, "...probably going to evolve to two, where there´s the innovative business and the value business, " in a January 8th interview. This news excites analysts because a split would make sense and would turn eyes away from its pipeline and base business to financial engineering.

TheStreet.com, website of infamous stock picker Jim Cramer, has reiterated a buy rating on Pfizer with a rating score of A-.

Read the entire press release issued by TheStreet.com about Pfizer Inc. here: http://www.thestreet.com/story/11813258/1/pfizer-inc-stock-buy-recommendation-reiterated-pfe.html?puc=yahoo&cm_ven=YAHOO

Merck & Co. Inc. recently announced that it is taking its cholesterol management drug, Tredaptive, off the market. The decision was based on preliminary data from a long term safety study.

Read the entire press release about Merck & Co. Inc. here: http://finance.yahoo.com/news/merck-stop-selling-tredaptive-231852003.html

Sam Isaly´s Orbimed Advisors, a large health care fund investing in healthcare companies, reported a position of 4.6 million shares in Merck, a 33% increase from three months earlier.

Eli Lilly and Company´s brain-plaque diagnostic was approved for use in adult patients by European health regulators on Tuesday. Their imaging agent is used to detect brain plaques that are considered a possible cause of Alzheimer´s disease. This radioactive diagnostic called Amyvid, was approved for use in the United States last April. The brain plaques were previously only detectable through autopsy.

Read the entire press release about Eli Lilly and Company here: http://www.reuters.com/article/2013/01/15/lilly-diagnostic-idUSL2N0AKJRH20130115?feedType=RSS&feedName=rbssHealthcareNews&rpc=43

Sign up to receive detailed reports and stock picks at http://www.PremierEquityReports.com. For real-time trade updates, follow our award winning hedge fund trader on Twitter @StockBrainiac. Premier Equity Reports also offers a FREE text message alert service to ensure that you receive all alerts. Simply text "reports" to 63566.

Premier Equity Reports is the U.S. leader in equity reports, offering quality reports to investors looking for the most undervalued companies in the market. Premier Equity Reports provides its subscribers with timely information and exclusive analysis on U.S. companies with substantial upside potential. Premier Equity Reports is the #1 free financial newsletter in the industry. Sign up now and see why thousands have joined already.

Disclosure: PremierEquityReports.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Premier Equity Reports is a wholly owned entity of Equities Awareness Group LLC. Equities Awareness Group LLC has been compensated one hundred thousand dollars for marketing awareness on Crown Marketing Inc. Please read our report and visit our website, for complete risks and disclosures.

 Contact Information:
 Equities Awareness Group LLC
 Michael Perinotti
 mike@equitiesag.com
 http://www.EquitiesAG.com
 +1-201-917-5934
 Third Party Publishing Provider: FNNewswire,  a FN Media Group,  LLC Company.